Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Focus' Simplexa becomes first FDA-cleared H1N1 diagnostic

This article was originally published in Clinica

Executive Summary

The US FDA has granted the first 510(k) clearance for an H1N1 test – Focus Diagnostics' Simplexa Influenza A H1N1 (2009) product. Previously, tests for the virus were only available through an emergency use authorisation (EUA), which allows the use of unapproved medical products during public health emergencies. The latest clearance means that the Simplexa test will still be available once the emergency expires. The test, which runs on the 3M Integrated Cycler, identifies H1N1 RNA using real-time reverse transcription PCR. It received an EUA in October 2009 (www.clinica.co.uk, 19 October 2009). Focus, a wholly-owned subsidiary of Quest Diagnostics, also CE marked it for sale in Europe in November 2009.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel